CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma

Autor Quintás-Cardama, Alfonso
Vydáno v Oncotarget (2018)

Molecular biology of bcr-abl1–positive chronic myeloid leukemia

Autor Quintás-Cardama, Alfonso, Cortes, Jorge
Vydáno 2009

Bullet ‘Manicure’: Does Lead Prevent Hydroxyurea-induced Cutaneous Toxicity?

Autor Falchi, Lorenzo, Quintás-Cardama, Alfonso
Vydáno v Jpn J Clin Oncol (2014)

MOLECULAR PATHWAYS: JAK/STAT PATHWAY: MUTATIONS, INHIBITORS, AND RESISTANCE

Autor Quintás-Cardama, Alfonso, Verstovsek, Srdan
Vydáno v Clin Cancer Res (2013)

The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans

Autor Pant, Vinod, Quintás-Cardama, Alfonso, Lozano, Guillermina
Vydáno 2012

ADVANCES AND CONTROVERSIES IN THE DIAGNOSIS, PATHOGENESIS, AND TREATMENT OF SYSTEMIC MASTOCYTOSIS

Autor Quintás-Cardama, Alfonso, Jain, Nitin, Verstovsek, Srdan
Vydáno v Cancer (2011)

The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome

Autor Larsson, Connie A., Cote, Gilbert, Quintás-Cardama, Alfonso
Vydáno 2013

Investigational Immunotherapeutics for B-Cell Malignancies

Autor Quintás-Cardama, Alfonso, Wierda, William, O'Brien, Susan
Vydáno v J Clin Oncol (2010)

Monitoring Molecular Response in Chronic Myeloid Leukemia

Autor Cortes, Jorge, Quintás-Cardama, Alfonso, Kantarjian, Hagop M.
Vydáno v Cancer (2010)

Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia

Autor Quintás-Cardama, Alfonso, Han, Xin, Kantarjian, Hagop, Cortes, Jorge
Vydáno 2009

Early Cytogenetic and Molecular Response During First-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase: Long-Term Implications

Autor Quintás-Cardama, Alfonso, Cortes, Jorgé E., Kantarjian, Hagop M.
Vydáno 2011

p53 pathway dysfunction in AML: beyond TP53 mutations

Autor Post, Sean M., Kornblau, Steven M., Quintás-Cardama, Alfonso
Vydáno v Oncotarget (2017)

Prognostic Impact of the MDM2(SNP309) Allele in Leukemia and Lymphoma

Autor Post, Sean M., Pant, Vinod, Abbas, Hussein, Quintás-Cardama, Alfonso
Vydáno 2010

Evolution of Therapies for Chronic Myelogenous Leukemia

Autor Santos, Fabio P S, Kantarjian, Hagop, Quintás-Cardama, Alfonso, Cortes, Jorge
Vydáno 2011

THE RISE AND FALL OF GAKEKEEPER MUTATIONS? THE BCR-ABL1(T315I) PARADIGM

Autor Gibbons, Don L., Pricl, Sabrina, Cortes, Jorge, Quintás-Cardama, Alfonso
Vydáno v Cancer (2011)

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability

Autor Pant, Vinod, Xiong, Shunbin, Iwakuma, Tomoo, Quintás-Cardama, Alfonso, Lozano, Guillermina
Vydáno 2011

Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia

Autor Quintás-Cardama, Alfonso, Kantarjian, Hagop, Pierce, Sherry, Cortes, Jorge, Verstovsek, Srdan
Vydáno 2013

Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

Autor Quintás-Cardama, Alfonso, Sever, Matjaz, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Vydáno v Leuk Lymphoma (2013)

SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH POLYCYTHEMIA VERA

Autor Sever, Matjaz, Quintás-Cardama, Alfonso, Pierce, Sherry, Zhou, Lingsha, Kantarjian, Hagop, Verstovsek, Srdan
Vydáno 2013

PREDICTING OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT ANY TIME DURING TYROSINE KINASE INHIBITOR THERAPY

Autor Quintás-Cardama, Alfonso, Choi, Sangbum, Kantarjian, Hagop, Jabbour, Elias, Huang, Xuelin, Cortes, Jorge
Vydáno 2014